Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

被引:19
作者
Song, Jehun [1 ]
Kang, Seongmin [1 ]
Choi, Seung Won [1 ]
Seo, Kwang Won [2 ]
Lee, Sunggun [3 ]
So, Min Wook [4 ]
Lim, Doo-Ho [1 ]
机构
[1] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Rheumatol,Dept Internal Med, 877 Bangeojinsunhwan Doro, Ulsan 44033, South Korea
[2] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Pulm & Crit Care Med,Dept Internal Med, Ulsan, South Korea
[3] Inje Univ, Haeundae Paik Hosp, Coll Med, Div Rheumatol,Dept Internal Med, Busan, South Korea
[4] Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Rheumatol, Yangsan, South Korea
关键词
Coronavirus; COVID-19; Pneumonia; Rheumatoid arthritis; Disease-modifying antirheumatic drugs; INFECTIONS;
D O I
10.1007/s00296-020-04584-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [21] Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis
    Costa, Neide Tomimura
    Veiga Iriyoda, Tatiana Mayumi
    Alfieri, Daniela Frizon
    Colado Simao, Andrea Name
    Dichi, Isaias
    INFLAMMOPHARMACOLOGY, 2018, 26 (05) : 1151 - 1164
  • [22] Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
    Joo, Young Bin
    Jung, Seung Min
    Park, Yune-Jung
    Kim, Ki-Jo
    Park, Kyung-Su
    JOURNAL OF RHEUMATIC DISEASES, 2022, 29 (03): : 162 - 170
  • [23] Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs
    Kim, Seoyoung C.
    Solomon, Daniel H.
    Liu, Jun
    Franklin, Jessica M.
    Glynn, Robert J.
    Schneeweiss, Sebastian
    AMERICAN JOURNAL OF MEDICINE, 2015, 128 (05) : 539.e7 - 539.e17
  • [24] Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis
    Neide Tomimura Costa
    Tatiana Mayumi Veiga Iriyoda
    Daniela Frizon Alfieri
    Andréa Name Colado Simão
    Isaias Dichi
    Inflammopharmacology, 2018, 26 : 1151 - 1164
  • [25] Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    DeWitt, Esi Morgan
    Li, Yanhong
    Curtis, Jeffrey R.
    Glick, Henry A.
    Greenberg, Jeffrey D.
    Anstrom, Kevin J.
    Kremer, Joel M.
    Reed, George
    Schulman, Kevin A.
    Reed, Shelby D.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (02) : 127 - 136
  • [26] PARTICULARITIES OF TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Schiotis, Ruxandra Elena
    Gosa, Dana
    Bocsan, Corina
    Suciu, Soimita
    Buzoianu, Anca Dana
    FARMACIA, 2017, 65 (03) : 479 - 484
  • [27] Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis
    Nandi, Pradip
    Kingsley, Gabrielle H.
    Scott, David L.
    CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (03) : 251 - 256
  • [28] Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: A systematic review
    Maese, Jesus
    Diaz del Campo, Petra
    Seoane-Mato, Daniel
    Guerra, Mercedes
    Canete, Juan D.
    REUMATOLOGIA CLINICA, 2018, 14 (02): : 81 - 89
  • [29] Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs
    Haruko Ideguchi
    Shigeru Ohno
    Hideaki Hattori
    Akiko Senuma
    Yoshiaki Ishigatsubo
    Arthritis Research & Therapy, 8
  • [30] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655